Marked Decreased Tracer Binding in 123I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report

Departments of ∗Neurology

†Radiology

‡Quantitative Health Sciences

§Psychiatry and Psychology, Mayo Clinic, Rochester, MN.

Address correspondence and reprint requests to Toji Miyagawa, MD, Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905; E-mail: [email protected]

This work is supported by the National Institutes of Health (grants U01 NS100620, P30 AG62677, R34 AG056639), GE Healthcare, Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, Little Family Foundation, and Ted Turner and Family LBD Functional Genomics Program.

Conflicts of Interest and Source of Funding: J.A.F. serves as a paid consultant for Medtronic, Inc. K.K. serves as a paid consultant for Biogen and receives research support from Avid Radiopharmaceuticals, Eli Lilly. V.J.L. serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc, AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). B.F.B. receives honoraria for SAB activities for the Tau Consortium and receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. The other authors have no conflicts of interest to declare.

留言 (0)

沒有登入
gif